Successful Portfolios LLC Sells 184 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Successful Portfolios LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,693 shares of the biopharmaceutical company’s stock after selling 184 shares during the period. Successful Portfolios LLC’s holdings in Gilead Sciences were worth $207,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Johanson Financial Advisors Inc. grew its position in shares of Gilead Sciences by 202.2% during the 2nd quarter. Johanson Financial Advisors Inc. now owns 12,222 shares of the biopharmaceutical company’s stock worth $940,000 after purchasing an additional 8,177 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd grew its position in shares of Gilead Sciences by 18.1% during the 2nd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 3,923 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 600 shares in the last quarter. Sound Income Strategies LLC grew its position in shares of Gilead Sciences by 26.8% during the 2nd quarter. Sound Income Strategies LLC now owns 1,352 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 286 shares in the last quarter. Cordasco Financial Network grew its position in shares of Gilead Sciences by 15.0% during the 2nd quarter. Cordasco Financial Network now owns 4,526 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 589 shares in the last quarter. Finally, Manning & Napier Group LLC grew its position in shares of Gilead Sciences by 6.5% during the 2nd quarter. Manning & Napier Group LLC now owns 441,630 shares of the biopharmaceutical company’s stock worth $33,978,000 after purchasing an additional 26,953 shares in the last quarter. Hedge funds and other institutional investors own 78.74% of the company’s stock.

In related news, CAO Diane E. Wilfong sold 12,264 shares of Gilead Sciences stock in a transaction on Monday, May 4th. The shares were sold at an average price of $80.09, for a total transaction of $982,223.76. Following the completion of the transaction, the chief accounting officer now owns 23,685 shares of the company’s stock, valued at $1,896,931.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now directly owns 27,204 shares of the company’s stock, valued at approximately $2,155,372.92. The disclosure for this sale can be found here. Insiders have sold 32,905 shares of company stock valued at $2,633,707 in the last ninety days. Insiders own 0.13% of the company’s stock.

GILD has been the topic of a number of analyst reports. Cowen restated a “buy” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Monday, April 13th. SunTrust Banks upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating and increased their price target for the stock from $70.00 to $73.00 in a research report on Tuesday, May 26th. Cantor Fitzgerald increased their price target on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Tuesday, June 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $97.00 price target on shares of Gilead Sciences in a research report on Monday, June 22nd. Five equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $79.65.

GILD stock opened at $76.68 on Tuesday. The company has a fifty day moving average price of $75.57 and a 200-day moving average price of $72.66. The company has a market capitalization of $96.19 billion, a P/E ratio of 19.71, a PEG ratio of 3.32 and a beta of 0.70. Gilead Sciences, Inc. has a 52-week low of $60.89 and a 52-week high of $85.97. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.57 by $0.11. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.67 earnings per share. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.64 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Friday, June 12th were paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a dividend yield of 3.55%. The ex-dividend date of this dividend was Thursday, June 11th. Gilead Sciences’s payout ratio is currently 44.30%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Why Invest in High-Yield Dividend Stocks?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.